Ronald George Hauser III, MD
Associate Professor of Laboratory MedicineCards
About
Research
Publications
2025
Natriuretic peptide testing in veterans hospitalized with heart failure: Potential differences by sex
Gandhi P, Runels T, Han L, Skanderson M, Bastian L, Brandt C, Hauser R, Feder S, Rodwin B, Farmer M, Bean-Mayberry B, Placide S, Gaffey A, Akgün K. Natriuretic peptide testing in veterans hospitalized with heart failure: Potential differences by sex. Heart & Lung 2025, 71: 25-31. PMID: 39970822, DOI: 10.1016/j.hrtlng.2025.02.001.Peer-Reviewed Original ResearchConceptsNatriuretic peptide testingHeart failure hospitalizationFacility characteristicsVeterans Affairs Healthcare SystemPeptide testingSex-based differencesFacility-related factorsSex-stratified modelsAssociated with increased likelihoodAssociated with decreased likelihoodHealthcare systemHF diagnosisEjection fractionCardiac comorbiditiesFailure hospitalizationClinical outcomesLogistic regressionAtrial fibrillationHeart failureVeteransClinical covariatesPatientsAdmissionSexAssociationAssociations between blood donors, component modifications, and the alloimmunization of transfusion recipients
Yu H, Karafin M, Tormey C, Goel R, Spencer B, Hendrickson J, Hauser R. Associations between blood donors, component modifications, and the alloimmunization of transfusion recipients. Transfusion 2025, 65: 588-603. PMID: 39821794, DOI: 10.1111/trf.18135.Peer-Reviewed Original ResearchRisk of RBC alloimmunizationRed blood cell unitsRed blood cellsTransfusion recipientsBlood donorsRBC alloimmunizationMultivariate conditional logistic regression analysisConditional logistic regression analysisRisk of alloimmunizationIrradiated red blood cellsCase-control studyLogistic regression analysisSickle cell diseaseAlloantibody formationAlloimmunization eventsRecipient variablesAlloimmunizationRecipient EpidemiologyRecipient diagnosisSub-analysisDecreased riskCell diseaseOlder donorsLow riskTransfusionCorrigendum: Combining Charlson comorbidity and VACS indices improves prognostic accuracy for all-cause mortality for patients with and without HIV in the Veterans Health Administration
McGinnis K, Justice A, Marconi V, Rodriguez-Barradas M, Hauser R, Oursler K, Brown S, Bryant K, Tate J. Corrigendum: Combining Charlson comorbidity and VACS indices improves prognostic accuracy for all-cause mortality for patients with and without HIV in the Veterans Health Administration. Frontiers In Medicine 2025, 11: 1532350. PMID: 39845833, PMCID: PMC11750659, DOI: 10.3389/fmed.2024.1532350.Peer-Reviewed Original Research
2024
National rollout of a medication safety dashboard to improve testing for latent infections among biologic and targeted synthetic disease‐modifying agent users within the Veterans Health Administration
Schmajuk G, Ware A, Li J, Tarasovsky G, Shiboski S, Barton J, Miller K, Mitchell H, Dana J, Reiter K, Wahl E, Rozenberg‐Ben‐Dror K, Hauser R, Whooley M. National rollout of a medication safety dashboard to improve testing for latent infections among biologic and targeted synthetic disease‐modifying agent users within the Veterans Health Administration. Health Services Research 2024, 60: e14363. PMID: 39056425, PMCID: PMC11782092, DOI: 10.1111/1475-6773.14363.Peer-Reviewed Original ResearchConceptsVeterans Affairs Healthcare SystemVA facilitiesVeterans Health AdministrationAudit log dataInterrupted time seriesPost-deploymentFrequency of sessionsWeeks post-deploymentFacility levelNational rolloutEHR dataHealth AdministrationHealthcare personnelHealthcare systemUnited States Veterans Affairs healthcare systemPercentage of patientsScreening dataEHRDashboard deploymentFacility personnelStudy periodSessionsScreeningUnited StatesFacilitiesVeteran's Health Administration HIV Care Continuum: 2019 vs 2022
Maier M, Beste L, Lowy E, Hauser R, Van Epps P, Yakovchenko V, Rogal S, Chartier M, Ross D. Veteran's Health Administration HIV Care Continuum: 2019 vs 2022. Open Forum Infectious Diseases 2024, 11: ofae382. PMID: 39086463, PMCID: PMC11288371, DOI: 10.1093/ofid/ofae382.Peer-Reviewed Original ResearchHuman immunodeficiency virusHIV care continuumViral suppressionVL resultsViral loadCare continuumFactors associated with viral suppressionTime of HIV diagnosisHuman immunodeficiency virus careRetrospective cohort analysisMultivariate logistic regressionVirologic suppressionImmunodeficiency virusHIV diagnosisVeterans Health AdministrationReceipt of careCohort analysisHealth care institutionsPWHCare qualityVHA careHealth AdministrationCare institutionsCareVHABlood type as a risk factor for pancreatic ductal adenocarcinoma.
Rahimi Larki N, Skanderson M, Tate J, Levinson R, Hauser R, Brandt C, Yang Y, Justice A, Wang L. Blood type as a risk factor for pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2024, 42: 10559-10559. DOI: 10.1200/jco.2024.42.16_suppl.10559.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinoma riskVeterans Health AdministrationRisk of pancreatic ductal adenocarcinomaNon-O blood typeNeighborhood-level socioeconomic dataIntegrated healthcare systemHigh risk of pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaAssociated with higher riskAssociated with increased riskUnited StatesHealth AdministrationOutpatient encountersHealthcare systemBaseline ageAlcohol useIndex dateAssociation of blood typeCancer deathWhite populationSocioeconomic dataBlack patientsDiverse populationsRisk factorsBlood typeEstimating risk for pancreatic cancer among 9.4 million veterans in care.
Wang L, Rahimi Larki N, Skanderson M, Tate J, Hauser R, Brandt C, Yang Y, Justice A. Estimating risk for pancreatic cancer among 9.4 million veterans in care. Journal Of Clinical Oncology 2024, 42: 10544-10544. DOI: 10.1200/jco.2024.42.16_suppl.10544.Peer-Reviewed Original ResearchVeterans Health AdministrationGeneral populationAlcohol useIntegrated health systemElectronic health recordsTen-year riskHistory of cancerLoss to follow-upFollow-upEvaluated model discriminationMedian baseline ageCox proportional hazards modelsRisk prediction modelHealth recordsProportional hazards modelHealth systemHealth AdministrationMultivariate Cox proportional hazards modelSmoking statusCharlson Comorbidity IndexBaseline ageClinical reasoningRange of risksHazards modelFinal predictorsDevelopment and Validation of Case-Finding Algorithms to Identify Pancreatic Cancer in the Veterans Health Administration
Mezzacappa C, Larki N, Skanderson M, Park L, Brandt C, Hauser R, Justice A, Yang Y, Wang L. Development and Validation of Case-Finding Algorithms to Identify Pancreatic Cancer in the Veterans Health Administration. Digestive Diseases And Sciences 2024, 69: 1507-1513. PMID: 38453743, DOI: 10.1007/s10620-024-08324-w.Peer-Reviewed Original ResearchElectronic health recordsVeterans Health AdministrationHealth AdministrationElectronic health records data elementsElectronic health record dataDiagnosis of exocrine pancreatic cancerNational Cancer RegistryCancer RegistryHealth recordsExocrine pancreatic cancerOncology settingOutpatient encountersInpatient encountersData elementsExpert adjudicationPancreatic ductal adenocarcinomaEpidemiological studiesRandom sampleInterquartile rangeIdentification of patientsRange of patientsPancreatic cancerVeteransLate diagnosisExcellent PPVCombining Charlson comorbidity and VACS indices improves prognostic accuracy for all-cause mortality for patients with and without HIV in the Veterans Health Administration
McGinnis K, Justice A, Marconi V, Rodriguez-Barradas M, Hauser R, Oursler K, Brown S, Bryant K, Tate J, Study F. Combining Charlson comorbidity and VACS indices improves prognostic accuracy for all-cause mortality for patients with and without HIV in the Veterans Health Administration. Frontiers In Medicine 2024, 10: 1342466. PMID: 38356736, PMCID: PMC10864663, DOI: 10.3389/fmed.2023.1342466.Peer-Reviewed Original ResearchCharlson Comorbidity IndexVACS IndexHIV RNAVeterans Health AdministrationComorbid diseasesNon-AIDS conditionsCongestive heart failureAssociated with CD4Risk of mortalityMedian ageHepatitis C.Older age groupsCharlson comorbidityCD4Prognostic accuracyHeart failurePWoHComorbidity indexVA careKidney diseasePWHHIVMatched comparatorsBaseline predictorsClinical biomarkersDecreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.Peer-Reviewed Original ResearchSickle cell diseaseDelayed hemolytic transfusion reactionQuality-adjusted life expectancyAlloimmunized patientsPatient populationRed blood cell alloimmunizationCell diseaseCost-effective interventionMedical expenditure of patientsHealth system perspectiveExpenditure of patientsIncremental cost-effectiveness ratioHemolytic transfusion reactionsUnited StatesMarkov cohort simulationCost-effectiveAverage patient populationCost-effectiveness ratioBirth cohortAnalytical time horizonAntibody historyCohort simulationTransfusionTransfusion reactionsLife expectancy
News
News
Get In Touch
Contacts
Academic Office Number